Episode Details
Back to Episodes
Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis
Published 8 months, 3 weeks ago
Description
In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement methods and the potential for using depth of response as an early signal in drug development.